Atopic dermatitis was, for most of medical history, managed as a skin condition — topical corticosteroids, moisturizers, and the frustrating advice to "avoid triggers." The recognition that moderate-to-severe AD is a systemic type 2 inflammatory disease driven by IL-4, IL-13, and IL-31 dysregulation transformed the research agenda. Dupilumab's approval in 2017 validated the cytokine-targeting approach definitively. The 2026 pipeline has deepened it: multiple JAK inhibitors now approved, tralokinumab and lebrikizumab offering IL-13-selective alternatives, nemolizumab directly targeting the itch pathway, and trials now asking whether early biologic intervention in children can modify disease course rather than just control symptoms.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Quick Summary
Atopic dermatitis is the most common chronic inflammatory skin disease globally, with a prevalence of 15–20% in children and 2–5% in adults. In 2026, over 400 active trials are recruiting. Approved since dupilumab (2017): tralokinumab (Adbry, 2022), lebrikizumab (Ebglyss, 2023), and three oral JAK inhibitors (abrocitinib, upadacitinib, baricitinib). Current trials are targeting itch via IL-31/nemolizumab, OX40L pathway (amlitelimab), and combination regimens for dupilumab partial responders.
ClinicalMetric Analysis
- Dupilumab partial responders aren't a uniform group — and the right next biologic depends on why the response is partial. Patients with significant residual itch despite good eczema control likely have ongoing IL-31 signaling that dupilumab doesn't target — making nemolizumab the mechanistically appropriate add-on. Patients with poorly controlled skin disease despite dupilumab may benefit from switching to an IL-13-selective agent (tralokinumab, lebrikizumab) or moving to a JAK inhibitor for broader cytokine suppression. The amlitelimab OX40L approach is the most upstream option — blocking the initiating signal before IL-4, IL-13, and IL-31 are each independently activated. Prescribers who default to dose escalation or switching within the same mechanistic class are missing the pharmacological differentiation now available.
- JAK inhibitor cardiovascular risk warnings in AD are being over-applied from an incomparable patient population. ORAL Surveillance — which generated the class warning — enrolled patients ≥50 years old with RA and at least one cardiovascular risk factor. The dermatology prescribing population for JAK inhibitors is predominantly younger adults with AD and without established CVD. The risk-benefit calculation for a 28-year-old with severe refractory AD is not the same as for a 65-year-old with RA and prior MI. Dermatologists should make patient-specific risk assessments rather than applying a blanket avoidance policy extrapolated from an incomparable trial population.
- Early intervention trials in infants with severe eczema are testing prevention of the atopic march — a fundamentally different goal than symptom control. The sequential development from severe early AD to food allergy to allergic rhinitis to asthma is well-documented epidemiologically. Whether aggressive cytokine suppression during the first 6–36 months can interrupt this sequence is being tested in prevention trials. If the atopic march is truly IL-4/IL-13-dependent in its early stages, early biologic intervention could prevent asthma in a population currently expected to develop it — changing the treatment decision from "controlling eczema" to "preventing respiratory disease."
Where the Treatment Landscape Stands in 2026
Dupilumab (Dupixent) — blocking the shared IL-4/IL-13 receptor — remains the most widely used biologic, but approximately 30–40% of patients are partial responders or don't respond adequately. This has driven the development of agents targeting more specific pathways:
- Selective IL-13 inhibitors: Tralokinumab (Adbry, LEO Pharma, approved 2022) and lebrikizumab (Ebglyss, Eli Lilly, approved 2023) block IL-13 specifically — not IL-4 — potentially offering a different tolerability profile and comparable efficacy to dupilumab. Phase 3 ECZTRA trials for tralokinumab showed 26–33% IGA 0/1 rates at 16 weeks vs. 12% placebo.
- Oral JAK inhibitors: Abrocitinib (Cibinqo), upadacitinib (Rinvoq), and baricitinib (Olumiant) offer rapid response — significant itch relief within 2–4 days — at the cost of requiring CBC and lipid monitoring and cardiovascular risk stratification before prescribing.
- Nemolizumab (Nemluvio): Blocks the IL-31 receptor directly — targeting the itch pathway rather than upstream inflammation. FDA-approved in August 2024. In Phase 3 trials, 43% of patients achieved IGA 0/1 vs. 13% placebo at 16 weeks; itch NRS response (≥4-point reduction) was achieved in 56% vs. 21%.
- Next-generation pipeline: OX40/OX40L pathway (rocatinlimab, amlitelimab), TSLP targeting, IL-33 antibodies — for patients who have failed dupilumab or JAK inhibitors.
Key Trials Recruiting in 2026
Amlitelimab (OX40L Antibody) — Phase 3 AVOLVE Programme
Sanofi/Regeneron's amlitelimab blocks OX40 ligand — a central T-cell activation signal in AD pathogenesis. AVOLVE-1 and AVOLVE-2 Phase 3 trials are enrolling adults with moderate-to-severe AD who have failed or are intolerant to dupilumab. Phase 2b showed 46% EASI-75 response at 16 weeks. What makes this compound particularly interesting is early evidence suggesting extended remission after stopping treatment — disease modification rather than just control. That's a different category of claim than any currently approved biologic makes. Eligibility requires EASI ≥16, IGA ≥3, and documented dupilumab inadequate response.
Nemolizumab Combination and Extension Studies
Following FDA approval of nemolizumab in 2024, 2026 trials are investigating combination with topical corticosteroids in adolescents (12–17), long-term itch control and sleep quality outcomes, and dual-pathway combination with dupilumab. Itch is the primary driver of quality-of-life impairment in AD — it disrupts sleep, impairs concentration, and causes behavioral changes in children. Trials measuring Worst Pruritus NRS ≥7 at baseline are specifically targeting the population with most burden from this symptom.
JAK Inhibitor Head-to-Head Studies
With three oral JAK inhibitors approved in the US and EU, head-to-head comparisons against dupilumab are underway. JADE COMPARE (abrocitinib vs. dupilumab) results showed abrocitinib 200 mg superior to dupilumab on itch NRS at week 2 (earlier onset) but comparable on EASI and IGA at 16 weeks. New trials directly compare abrocitinib vs. upadacitinib on both efficacy and cardiovascular safety endpoints. Patient selection for these trials often prioritizes those who need rapid itch relief and prefer oral over injectable therapy.
Pediatric and Adolescent Trials
AD is most prevalent in children — 15–20% vs. 2–5% in adults — and the available approved options in pediatric populations have historically lagged behind adult approvals. Active recruiting trials include: dupilumab in infants ages 6 months–5 years (extension studies evaluating long-term safety), tralokinumab in adolescents 12–17, and ruxolitinib cream (Opzelura) in children ages 2–11 for mild-to-moderate disease. The disease-modifying question is particularly significant in this population: if early biologic intervention can reduce the atopic march (AD leading to asthma and allergic rhinitis), the implications extend well beyond skin.
Topical and Non-Biologic Approaches
Not all trials require injections or systemic drugs. Active 2026 studies include tapinarof cream (Vtama) extension to atopic dermatitis after psoriasis approval, crisaborole PDE4 inhibitor combination studies, and microbiome-modulating interventions targeting Staphylococcus aureus skin colonization. These trials typically have fewer exclusion criteria and are particularly relevant for patients with mild-to-moderate disease who don't meet the severity threshold for biologic trials.
Eligibility — What Most Trials Require
| Criterion | Typical Requirement |
|---|---|
| Disease severity | EASI ≥16 (moderate-to-severe) or IGA 3–4 |
| Prior treatment failure | Inadequate response to mid-to-high potency topical corticosteroids (most trials) |
| Dupilumab history | Varies: some require dupilumab failure, others exclude dupilumab users |
| Disease duration | ≥1 year of chronic AD (not acute flare) |
| Washout periods | Systemics (4 weeks), biologics (4–12 weeks), phototherapy (4 weeks) |
How to Measure Your Eczema Severity Before Applying
Trials use standardized scoring tools that you should understand before contacting a study site — arriving with documented scores significantly speeds up pre-screening:
- EASI (Eczema Area and Severity Index): Body surface area multiplied by intensity scores across 4 body regions. Score 0–72. Moderate = 7.1–21.0; severe = 21.1–72.
- IGA (Investigator Global Assessment): 0 (clear) to 4 (severe). Most trials require IGA ≥3 at screening.
- Pruritus NRS: 0–10 itch scale. Itch-targeted trials often require NRS ≥7 (worst 24-hour itch score over the past week).
- DLQI (Dermatology Life Quality Index): Quality-of-life impact scoring used as secondary endpoint in most trials.
Your dermatologist can formally score these at a pre-screening visit. Documentation of inadequate response to topical treatments is the single most important eligibility factor for most biologic trials — having that documented in your medical record before contacting a site saves weeks of back-and-forth.
What to Expect in an Atopic Dermatitis Trial
Screening period (2–4 weeks)
Washout of prior treatments, baseline photographs, disease scoring, blood tests, and potentially skin biopsies in mechanistic sub-studies. During washout, only emollients and low-potency topicals are permitted. This period is the one most patients find frustrating — you're managing your disease with less than usual while you wait to find out if you qualify.
Treatment period (16–52 weeks)
Most Phase 3 trials have a 16-week placebo-controlled induction period followed by an open-label extension where all participants receive active drug. Biologic injections are typically self-administered every 2–4 weeks after initial training. JAK inhibitor trials involve daily oral dosing with regular blood monitoring (CBC, lipids, liver enzymes every 4–8 weeks).
Primary endpoints
EASI-75 (75% improvement from baseline) and IGA 0/1 (clear or almost clear skin) at 16 weeks are the standard co-primary endpoints across Phase 3 AD trials. Secondary endpoints include itch NRS, sleep disturbance scores, and quality of life measures. Early response is assessed at weeks 4 and 8 — and JAK inhibitors in particular show significant itch improvement that early.
Find Eczema Trials Near You
Browse 400+ recruiting atopic dermatitis and eczema trials filtered by condition, phase, location, and eligibility.
Frequently Asked Questions
What new eczema treatments are in clinical trials in 2026?
Beyond approved biologics (dupilumab, tralokinumab) and JAK inhibitors (abrocitinib, upadacitinib), 2026 trials include: lebrikizumab combinations; nemolizumab for itch; anti-IL-31 therapies; TSLP blockers; and microbiome-based topical therapies targeting Staphylococcus aureus dysbiosis.
Can children with eczema join clinical trials?
Yes. Pediatric eczema trials are active across all age groups. Dupilumab is now approved down to 6 months old; trials continue for infants. JAK inhibitor trials have specific pediatric arms (ages 12+, with some studying younger children). Disease severity (IGA score, EASI score, BSA involvement) is the primary eligibility criterion.
What is the difference between a biologic and a JAK inhibitor for eczema?
Biologics (dupilumab, tralokinumab) are injected antibodies blocking specific cytokines (IL-4, IL-13). JAK inhibitors (abrocitinib, upadacitinib) are oral pills blocking intracellular signaling driving multiple inflammatory cytokines. Biologics are generally first-line for severe eczema; JAK inhibitors offer oral convenience but require monitoring for infections, lipids, and cardiac risk in older adults.